Skip to main content
x

Recent articles

The markets stress over Nuvectis

NXP800 yields neither severe thrombocytopenia, nor any responses.

Merck & Co gets in on the bispecific act

For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.

Regeneron keeps up its co-stimulatory crusade

The company’s CD38 x CD28 MAb is among recent clinical trial entrants.

ASH 2024 preview – more challenges to the BTK order

First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.

BioNTech puts a ring on Biotheus

A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.

Heartache for Syndax

Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.